2024 Spring Conference - Program

Veterinary Conference Agenda

Saturday, April 20, 2024

  Sunday, April 21, 2024
7:30am Cont. Breakfast & Registration   7:30am Cont. Breakfast
8:30am Meeting Begins   8:30am Meeting Begins
10:00am AM Break*   10:00am AM Break*
12:00pm Lunch Break*   12:00pm Lunch Break*
2:30pm PM Break*   2:30pm PM Break*
4:30pm Meeting Concludes   4:30pm Meeting Concludes
4:30pm Happy Hour Reception      

*Exibitor room open throughout all breaks


Saturday, April 20, 2024:

Cutaneous and Subcutaneous Mast Cell Tumors in Dogs
(Combined Clifford and Liptak) 
From the medical oncology aspect, we will discuss several controversial and new developments for dogs with MCT. This includes cytologic grading vs histological grading and where we see this being applied, the use of prednisone to down-size tumors before surgery, multiple mast cell tumors, and how to handle them, subcutaneous MCTs and how they differ from their cutaneous counterparts and the use of tigilanol tiglate (novel intratumoral injection) for select tumors. 

From the surgical oncology aspect, we will discuss the role of sentinel lymph node mapping in the management of dogs with cutaneous and subcutaneous MCTs, and wide surgical resection using the proportional and metric margin system

Appendicular Osteosarcoma (Combined Clifford and Liptak)
From the medical oncology aspect, we will discuss staging for dogs with OSA and what parameters play a role in prognosis; the use of liquid biopsy as an adjuvant to diagnose and monitor OSA; the role of chemotherapy; treatment of metastatic disease; and palliative care for OSA that can be performed in the primary care setting. 

From the surgical oncology aspect, we will discuss the surgical treatment options for the local tumor, such as limb amputation, partial limb amputation, and limb-sparing surgery; as well as non- surgical curative-intent treatment options, particularly stereotactic radiation therapy. 

Principles of Surgical Oncology (Liptak)
This lecture, we will review a range of surgical oncology principles. This includes workup options, clinical staging tests (including sentinel lymph node mapping and the importance and limitations of advance imaging modalities, particularly CT scan), surgical approaches and techniques (and why surgical options should not be based on whether the wound can be closed primarily or not), and postoperative specimen handling for histopathology. 

Apocrine Gland Anal Sac Adenocarcinoma in Dogs (Liptak)
For this lecture, we will discuss the diagnosis, clinical staging, treatment options and prognosis for dogs with apocrine gland anal sac adenocarcinoma (AGASACA). This will include new information based on an as-of-yet unpublished study of 1,331 surgically treated dogs with AGASACA with interesting and un- expected results, especially for dogs with AGASACA metastatic to the sublumbar lymph nodes at the time of diagnosis. 

Veterinary Oncology: What Can I Do in the Primary Care Setting?
Part 1: Diagnostics (Clifford)

This segment will focus on the primary care clinician and di- agnostics that should be performed in your clinic, Braf testing for transitional cell carcinoma, digital cytology, phenotyping for canine lymphoma, and the OncoK9® liquid biopsy test. 

Veterinary Oncology: What Can I Do in the Primary Care Setting?
Part 2: Treatments (Clifford)
We will cover the use of Laverdia®-CA1 for dogs with lymphoma, bisphosphonates for dogs with OSA, and the role of supportive medications (Appetite stimulants, pain medications etc). 

Sunday, April 21, 2024:

Oral Tumors, Part 1 (Clifford)
From the medical oncology aspect, we will discuss staging techniques for oral tumors and the signalment associated with our most common oral tumors, including melanoma, squamous cell carcinoma, and sarcomas. We will discuss the role of immunohistochemistry in differentiating sarcoma and amelanotic melanoma and, where appropriate, when adjuvant therapy is required using the melanoma vaccine or chemotherapy. 

Oral Tumors, Part 2 (Liptak)
From the surgical oncology aspect, we will discuss various surgical options for the management of cats and dogs with oral tumors, including mandibulectomy and maxillectomy procedures, their potential complications, and outcomes following these procedures. In doing so, we hope to bust the myth that oral surgery is not a recommended procedure for cats with oral tumors, particularly oral squamous cell carcinoma, because it definitely is! 

How to Read a Histopathology Report
and When to Ask for More! (Clifford) 
This lecture will describe the submitting clinician's and the pathologist's duties to get more from your reports. We will focus on when to ask for more, know when something is missing, and when specialized testing is warranted. 

What’s New in Oncology (Clifford)
This lecture will tackle the latest and greatest in veterinary oncology to include ImpriMed’s chemotherapy sensitivity assay, treatments for dogs with lymphoma, treatments for chemotherapy-induced diarrhea, and the future of immunotherapy with checkpoint inhibitors. 

Surgical and Histologic Margins (Liptak)
In this lecture, we will discuss surgical and histologic margins, the difference between these two margin systems, and how much we don’t know about both surgical and histologic margins. We will discuss controversies with clean-but-close or narrow margins, how much I dislike this terminology (!), and the Residual Tumor Classification Scheme and why we should all be using it.

Soft Tissue Sarcomas in Dogs and Cats (Liptak)
In this lecture, we will be discussing soft tissue sarcomas in dogs and cats, including vaccine-associated sarcomas in cats. In particular, surgical management of these tumors and how they are not necessarily as aggressive as we have previously been led to believe. We will also discuss the role (or not) of radiation therapy in the management of marginally resected or incompletely excised soft tissue sarcomas in dogs. 


The SDCVMA is a California Statutorily approved CE provider.